1. Volume 382, Issue 9900, Pages 1258-1267 (October 2013)
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2- year findings of the IVAN randomised controlled trial 
Prof Usha Chakravarthy, PhD, Prof Simon P Harding, MD, Chris A Rogers, PhD, Susan M Downes, MD, Prof Andrew J Lotery, MD, Lucy A Culliford, PhD, Prof Barnaby C Reeves, DPhil 
The Lancet 
Volume 382, Issue 9900, Pages (October 2013)
DOI: /S (13)
Copyright © 2013 Chakravarthy et al. Open Access article distributed under the terms of CC BY-NC-SA Terms and Conditions

2. Figure 1
Mean differences in best corrected distance visual acuity at 2 years
By drug (top) and by regimen (bottom). Black dashed line shows non-inferiority limit of −3·5 letters. Mean differences estimated with data from visits 0, 3, 6, 9, 12, 15, 18, 21, and 24, adjusted for centre size. 95% CIs given in parentheses and shown by bars.
The Lancet  , DOI: ( /S (13) )
Copyright © 2013 Chakravarthy et al. Open Access article distributed under the terms of CC BY-NC-SA Terms and Conditions

3. Figure 2 Secondary outcomes at 2 years
(A) By drug. (B) By regimen. 95% CIs given in parentheses and shown by bars. GMR=geometric mean ratio. MD=mean difference. OR=odds ratio.
The Lancet  , DOI: ( /S (13) )
Copyright © 2013 Chakravarthy et al. Open Access article distributed under the terms of CC BY-NC-SA Terms and Conditions

4. Figure 3
Change in best corrected distance visual acuity in CATT and IVAN at 2 years
(A) By drug. (B) By regimen. 95% CIs shown by bars. CATT=Comparison of Age-related macular degeneration Treatment Trials. IVAN=Inhibition of VEGF in Age-related choroidal Neovascularisation trial.
The Lancet  , DOI: ( /S (13) )
Copyright © 2013 Chakravarthy et al. Open Access article distributed under the terms of CC BY-NC-SA Terms and Conditions

5. Figure 4 Geographic atrophy in CATT and IVAN at 2 years
(A) By drug. (B) By regimen. 95% CIs shown by bars. CATT=Comparison of Age-related macular degeneration Treatment Trials. IVAN=Inhibition of VEGF in Age-related choroidal Neovascularisation trial.
The Lancet  , DOI: ( /S (13) )
Copyright © 2013 Chakravarthy et al. Open Access article distributed under the terms of CC BY-NC-SA Terms and Conditions

6. Figure 5 Safety outcomes in CATT and IVAN at 2 years
(A) By drug. (B) By regimen. 95% CIs shown by bars. CATT=Comparison of Age-related macular degeneration Treatment Trials. IVAN=Inhibition of VEGF in Age-related choroidal Neovascularisation trial.
The Lancet  , DOI: ( /S (13) )
Copyright © 2013 Chakravarthy et al. Open Access article distributed under the terms of CC BY-NC-SA Terms and Conditions